Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,200 employees in 76 countries, and markets its products in more than 180 countries.
Bangladesh Office of Novo Nordisk Pharma
Factory/ Plant Address:
Tongi, Gazipur, Dhaka; Bangladesh.
Novo nordisk set up a high-tech insulin manufacturing plant in Tongi. The plant, the third set up by the company in Asia after China and India and it is a tie-up between the Novo Nordisk and Eskayef Bangladesh Ltd, a leading local pharmaceutical company. The Nordisk-Eskayef plant will manufacture over 5 million vials a year, maintaining the high-quality standards followed by Novo Nordisk across the world. Novo Nordisk enjoys more than 80 percent share in the insulin segment of diabetic care market in Bangladesh.
Novo nordisk is working globally to raise awareness, improve access to care and address psychosocial aspects of diabetes to improve people’s lives through a program named, ‘Changing Diabetes®‘. Changing Diabetes® is also about working at the frontiers of research and development to improve treatments and create more opportunities for people with diabetes. This includes going beyond medicine to advocate for better education and support, helping people better manage their diabetes and live life on their own terms.